NeuroMetrix (NURO) Receives Chinese Patent Related to DPNCheck Core Technology

September 1, 2016 11:49 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

NeuroMetrix, Inc. (Nasdaq: NURO) announced that the State Intellectual Property Office of the People’s Republic of China has issued Chinese Patent No. ZL20118055305.7 for the core technology underlying the Company’s DPNCheck® device, which is a point-of-care test for peripheral neuropathies such as diabetic peripheral neuropathy (DPN). The patent claims cover the novel integrated design of the device that enables accurate and rapid measurement of sural nerve conduction, which is a standard neuropathy biomarker. Additional claims cover the automation algorithms and consumable biosensors.

China is dealing with an epidemic of diabetes. According to a recently published study in the Journal of the American Medical Association (JAMA), the prevalence of diabetes in the Chinese population has risen dramatically over the past decades to nearly 12% today. The International Diabetes Federation (IDF) estimated in 2014 that over 96 million people in China had diabetes. This represents nearly 25% of the IDF estimated worldwide population of 387 million people with diabetes.

The Company is partnering with Omron Corporation to introduce DPNCheck to the China healthcare market.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment